Therapy Area
Codagenix pursues RSV vaccine development amid unexpected challenges
Codagenix faces a late 2024 data readout following enrollment challenges in its paediatric RSV vaccine Phase I study.
Harmony Biosciences reports positive Phase II DM1 therapy data
Halia Therapeutics to test HT-6184 in MDS patients for first time
Merck to discontinue Phase III lung cancer trial due to futility
NIH commences tuberculous meningitis drug combination regimen trial
New guide, new endpoint: Studying hypoglycaemia for diabetic drug efficacy
